Israel-based medical portfolio company of The Trendlines Group, Gordian Surgical, has commenced the first human clinical trial of its TroClose1200 for laparoscopic surgery.
The TroClose1200 is an innovative trocar featuring an integrated closure mechanism which is used to open the abdomen to insert optical tools and other surgical equipment prior to surgery where the integrated closure mechanism also allows the closure of the incision.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The equipment is designed to improve safety while ensuring convenience and efficacy during the surgery.
Its release mechanism allows the insertion of sutures into the tissue at the beginning of the procedure, instead of inserting it at the end hence saving time involved in the procedure.
The sutures remains intact in one place throughout the operation and incisions are closed almost automatically after the TroClose1200 is removed.
Gordian Surgical medical director and Poriya Medical Center, Israel director of surgery Dr Nissim Geron said: “The innovative device functioned very well and allowed for closure of incisions that would have been very difficult to perform without the use of Gordian’s product.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“The product is safe, user-friendly and represents an important breakthrough in laparoscopic surgery.”
So far, the company had undertaken 13 successful procedures in Israel and India.
India-base laparoscopic surgeon, Dr Surendra Ugale said: “I am extremely satisfied with the TroClose1200.
“The device demonstrated excellent performance and would be a great asset for any bariatric surgery, most especially on morbidly obese patients.”
Image: Gordian Surgical’s TroClose1200. Photo: courtesy of PR Newswire Association LLC.
